CUBICIN SUMMARY
Cubicin® (daptomycin for injection) Rx only
CUBICIN contains daptomycin, a cyclic lipopeptide antibacterial agent derived from the fermentation of
Streptomyces roseosporus.
CUBICIN (daptomycin for injection) is indicated for the treatment of complicated skin and skin structure infections caused by susceptible strains of the following Gram-positive microorganisms (see also DOSAGE AND ADMINISTRATION):
Staphylococcus aureus (including methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis and Enterococcus faecalis
(vancomycin-susceptible strains only). Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative or anaerobic organisms (see CLINICAL STUDIES).
Daptomycin is not indicated for the treatment of pneumonia.
Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to daptomycin. Empiric therapy may be initiated while awaiting test results. Antimicrobial therapy should be adjusted as needed based upon test results.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN and other antibacterial drugs, CUBICIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
|
NEWS HIGHLIGHTS
Published Studies Related to Cubicin (Daptomycin)
Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. [2009.07]
OBJECTIVES: Two randomized Phase I studies in separate populations of healthy adult volunteers investigated the pharmacokinetics, safety and tolerability of daptomycin (Cubicin; Novartis Pharma AG, Basel, Switzerland) administered as a 2 min intravenous (iv) injection, relative to the currently licensed 30 min iv infusion... CONCLUSIONS: The similar pharmacokinetic and safety profiles of the two administration regimens suggest that the 2 min iv injection may be a convenient treatment option for both patients and healthcare professionals.
Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. [2009.05]
OBJECTIVES: Administering outpatient parenteral antimicrobial therapy in the community setting (CoPAT) is becoming more common with the increasing emphasis on controlling costs. However, few controlled trials have evaluated this treatment modality... CONCLUSIONS: With proper monitoring, stable patients can complete treatment for SAB/IE as outpatients in the community setting. Daptomycin is an appropriate option for this setting.
The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. [2009.03]
BACKGROUND: Results from previous trials suggest that daptomycin may result in faster clinical improvement than penicillinase-resistant penicillins or vancomycin for patients with complicated skin and skin structure infections. OBJECTIVE: The objective was to evaluate whether daptomycin treatment of cellulitis or erysipelas would result in faster resolution compared with vancomycin... CONCLUSIONS: There was no difference in the rate of resolution of cellulitis or erysipelas among patients treated with daptomycin or vancomycin. Daptomycin 4 mg/kg once daily appeared to be effective and safe for treating cellulitis or erysipelas.
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. [2008.12]
OBJECTIVES: In a prospective, randomized trial, daptomycin was non-inferior to standard therapy for Staphylococcus aureus bacteraemia and right-sided endocarditis. Since rates of infection due to methicillin-resistant S. aureus (MRSA) infection are increasing and treatment outcomes for bacteraemia caused by MRSA are generally worse than those observed with methicillin-susceptible S. aureus bacteraemia, clinical characteristics and treatment results in the trial's pre-specified subset of patients with MRSA were analysed... CONCLUSIONS: Daptomycin was an effective alternative to vancomycin/gentamicin for MRSA bacteraemia or right-sided endocarditis.
Clinical experience with daptomycin: bacteraemia and endocarditis. [2008.11]
Serious infections due to Staphylococcus aureus, especially those due to methicillin-resistant S... In addition, in a randomized controlled trial comparing daptomycin monotherapy with potentially synergistic therapy with either vancomycin or beta-lactam, both used in combination with an aminoglycoside, daptomycin achieved comparable outcomes but with significantly less nephrotoxicity.
Clinical Trials Related to Cubicin (Daptomycin)
Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD) [Suspended]
Daptomycin is an antibiotic that is affective against many strains of antibiotic resistant
microorganisms. This antibiotic would be appropriate for use in the intensive care unit
(ICU) considering the severity of illness and high risk for infection within this hospital
environment. While in the ICU, patients may develop acute renal failure. Approximately 75%
of ICU patients who develop acute renal failure will require some form of renal replacement
therapy until their kidneys recover. Continuous hemodialysis is becoming one of the most
common forms of dialysis in the ICU as it is a gentle type of dialysis provided over longer
periods of time. The current data demonstrating the ability of continuous hemodialysis to
remove daptomycin from the body is derived from in-vitro trials. The purpose of this trial
is to determine the extent of daptomycin removal from critically ill patients receiving
continuous hemodialysis. Findings from this trial will be used to develop new dosing
recommendations for daptomycin in continuous hemodialysis.
Study Comparing CUBICINŽ (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas [Completed]
This study is designed to investigate the difference in speed and degree of symptom
resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas
by evaluation of the following parameters:
- Time to erythema margin cessation to progress
- Time to defervescence
- Time to hospital discharge following relief of the presenting cellulitis or erysipelas
- Degree of improvement of the following signs and symptom of cellulitis or erysipelas
including
- Degree of improvement of cellulitis-related pain and swelling as reported by subjects
Additionally, the difference in frequency of Adverse Events between daptomycin and vancomycin
will be described.
Cubicin(R) for Complicated Post-Surgical Wound Infections [Terminated]
The purpose of the study is to describe the clinical efficacy of CUBICIN therapy in patients
with superficial and deep post-surgical Gram-positive wound infections
Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections [Terminated]
This is a Phase 4, randomized, open-label, multicenter, comparative study designed to further
evaluate the pharmacokinetics of intravenous (i. v.) daptomycin and the safety and efficacy of
daptomycin relative to comparator in the treatment of complicated skin and skin structure
infections in patients with renal impairment.
Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus [Completed]
The purpose of this study is to compare the safety and efficacy of daptomycin, an antibiotic,
to standard therapy in subjects who have infective endocarditis or bacteremia due to
Staphylococcus aureus (S. aureus).
|
